Novavax (NVAX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vor Biopharma (VOR) has outperformed Novavax (NVAX) over the past year, gaining 157.6% versus a gain of 15.5%. Over five years, VOR leads with a -92.0% price change compared with -96.6% for NVAX. Novavax is the larger company by market cap ($1.23 billion vs $1.18 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NVAX | VOR |
|---|---|---|
| Share price | $7.47 | $19.19 |
| Market cap | $1.23B | $1.18B |
| 1-day change | -3.24% | +3.62% |
| YTD return | +11.16% | +46.71% |
| 1-year return | +15.46% | +157.58% |
| 5-year return | -96.57% | -92.00% |
| P/E ratio (TTM) | — | 0.06 |
| EPS (TTM) | $-0.52 | $300.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $1.12B | — |
| Revenue growth (YoY) | +64.69% | — |
| Net income (latest FY) | $440.30M | $-695.98M |
| Gross margin | 93.50% | — |
| Operating margin | 40.30% | — |
| Net margin | 39.19% | — |
| 52-week high | $13.39 | $26.00 |
| 52-week low | $6.36 | $7.21 |
| Distance from 52-week high | -44.21% | -26.19% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +88.89% | +103.23% |
| Average volume | 6.67M | 945.67K |
| Shares outstanding | 165.01M | 61.43M |
| Employees | 749 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VOR has outperformed NVAX by 142.1 percentage points over the past year.
About Novavax
NVAX stock →Novavax, Inc., a biotechnology company, engages in the discovery, development, and commercialization of vaccines to prevent serious infectious diseases in the United States, Europe, and internationally. The company commercializes Nuvaxovid, a COVID-19 vaccine; and R21 Matrix-M adjuvant malaria vaccine.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 749 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
NVAX vs VOR FAQ
Which is bigger, Novavax or Vor Biopharma?
Novavax (NVAX) is larger, with a market capitalization of $1.23B compared with $1.18B for Vor Biopharma (VOR).
Which stock has performed better over the past year, NVAX or VOR?
VOR returned +157.58% over the past 12 months, compared with +15.46% for NVAX (price return, excluding dividends). Past performance does not predict future results.
Are Novavax and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.